Long-term outcomes of tislelizumab with chemotherapy for advanced squamous lung cancer
Reviews past records of people given tislelizumab with chemotherapy for advanced lung cancer.
Key facts
- Who runs it
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- A Retrospective Real-World Study Based on RATIONALE-307
- Status
- Recruiting
- People taking part
- 109 people, planned
- Started
- 28 Feb 2026
- Expected to end
- 31 Dec 2027
- Type of study
- Observational
- Record updated
- 27 March 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The study is looking for people with squamous lung cancer who took part in the RATIONALE-307 trial and were still alive when that trial ended. It looks back at their long-term survival data.
- Sex
- All sexes can join.
- Disease stage
- Squamous non-small cell lung cancer (NSCLC).
- Earlier treatment
- Must have taken part in the RATIONALE-307 trial.
Main reasons for not taking part
- A documented death before the RATIONALE-307 trial was completed
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Who cannot take part
- Patients who had a documented death before study completion in the RATIONALE-307 trial
Where in China
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical CollegeBeijing, ChinaContact: Wang ZhijieTaking people
About the trial
What the trial wants to find out
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in advanced squamous NSCLC patients from immunotherapy and to identify patients deriving greater clinical advantage.
The group in the trial
- Extension Cohort
Patients with squamous NSCLC who participated in the RATIONALE-307 trial and had no documented death before study completion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long-Term Efficacy and Safety Analysis of First-Line Tislelizumab in Patients With Advanced Squamous NSCLC: a Retrospective Real-World Study Based on RATIONALE-307
- Plain-language title
- Long-term outcomes of tislelizumab with chemotherapy for advanced squamous lung cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 27 March 2026